It is an MC4 receptor agonist developed for the treatment of obesity arising from POMC, proprotein convertase subtilisin/kexin type 1 (PCSK1), or LEPR deficiency. Here, POMC is linked to obesity due to melanocortin 4 receptor deficiency.